vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $185.2M, roughly 1.1× AMICUS THERAPEUTICS, INC.). AMICUS THERAPEUTICS, INC. runs the higher net margin — 0.9% vs -14.6%, a 15.5% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 23.7%). AMICUS THERAPEUTICS, INC. produced more free cash flow last quarter ($16.0M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 29.5%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
AXSM vs FOLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $185.2M |
| Net Profit | $-28.6M | $1.7M |
| Gross Margin | — | 85.7% |
| Operating Margin | -13.8% | 8.6% |
| Net Margin | -14.6% | 0.9% |
| Revenue YoY | 65.0% | 23.7% |
| Net Profit YoY | 61.9% | -88.5% |
| EPS (diluted) | $-0.55 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $185.2M | ||
| Q3 25 | $171.0M | $169.1M | ||
| Q2 25 | $150.0M | $154.7M | ||
| Q1 25 | $121.5M | $125.2M | ||
| Q4 24 | $118.8M | $149.7M | ||
| Q3 24 | $104.8M | $141.5M | ||
| Q2 24 | $87.2M | $126.7M | ||
| Q1 24 | $75.0M | $110.4M |
| Q4 25 | $-28.6M | $1.7M | ||
| Q3 25 | $-47.2M | $17.3M | ||
| Q2 25 | $-48.0M | $-24.4M | ||
| Q1 25 | $-59.4M | $-21.7M | ||
| Q4 24 | $-74.9M | $14.7M | ||
| Q3 24 | $-64.6M | $-6.7M | ||
| Q2 24 | $-79.3M | $-15.7M | ||
| Q1 24 | $-68.4M | $-48.4M |
| Q4 25 | — | 85.7% | ||
| Q3 25 | — | 88.5% | ||
| Q2 25 | — | 90.2% | ||
| Q1 25 | — | 90.7% | ||
| Q4 24 | — | 90.1% | ||
| Q3 24 | — | 90.6% | ||
| Q2 24 | — | 91.1% | ||
| Q1 24 | — | 87.7% |
| Q4 25 | -13.8% | 8.6% | ||
| Q3 25 | -27.0% | 20.3% | ||
| Q2 25 | -24.5% | -6.1% | ||
| Q1 25 | -46.9% | -6.3% | ||
| Q4 24 | -61.1% | 10.7% | ||
| Q3 24 | -59.8% | 15.3% | ||
| Q2 24 | -89.5% | 11.8% | ||
| Q1 24 | -89.7% | -25.1% |
| Q4 25 | -14.6% | 0.9% | ||
| Q3 25 | -27.6% | 10.2% | ||
| Q2 25 | -32.0% | -15.8% | ||
| Q1 25 | -48.9% | -17.3% | ||
| Q4 24 | -63.1% | 9.8% | ||
| Q3 24 | -61.7% | -4.8% | ||
| Q2 24 | -91.0% | -12.4% | ||
| Q1 24 | -91.1% | -43.9% |
| Q4 25 | $-0.55 | $0.00 | ||
| Q3 25 | $-0.94 | $0.06 | ||
| Q2 25 | $-0.97 | $-0.08 | ||
| Q1 25 | $-1.22 | $-0.07 | ||
| Q4 24 | $-1.54 | $0.05 | ||
| Q3 24 | $-1.34 | $-0.02 | ||
| Q2 24 | $-1.67 | $-0.05 | ||
| Q1 24 | $-1.44 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $293.5M |
| Total DebtLower is stronger | — | $392.7M |
| Stockholders' EquityBook value | $88.3M | $274.2M |
| Total Assets | $689.8M | $949.9M |
| Debt / EquityLower = less leverage | — | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $293.5M | ||
| Q3 25 | $325.3M | $263.8M | ||
| Q2 25 | $303.0M | $231.0M | ||
| Q1 25 | $300.9M | $250.6M | ||
| Q4 24 | $315.4M | $249.9M | ||
| Q3 24 | $327.3M | $249.8M | ||
| Q2 24 | $315.7M | $260.1M | ||
| Q1 24 | $331.4M | $239.6M |
| Q4 25 | — | $392.7M | ||
| Q3 25 | — | $392.0M | ||
| Q2 25 | — | $391.3M | ||
| Q1 25 | — | $390.7M | ||
| Q4 24 | — | $390.1M | ||
| Q3 24 | — | $389.5M | ||
| Q2 24 | — | $388.9M | ||
| Q1 24 | — | $388.4M |
| Q4 25 | $88.3M | $274.2M | ||
| Q3 25 | $73.7M | $230.4M | ||
| Q2 25 | $73.1M | $204.3M | ||
| Q1 25 | $53.2M | $193.6M | ||
| Q4 24 | $57.0M | $194.0M | ||
| Q3 24 | $92.9M | $178.8M | ||
| Q2 24 | $102.9M | $132.5M | ||
| Q1 24 | $144.0M | $130.7M |
| Q4 25 | $689.8M | $949.9M | ||
| Q3 25 | $669.3M | $868.8M | ||
| Q2 25 | $639.8M | $815.3M | ||
| Q1 25 | $596.7M | $789.8M | ||
| Q4 24 | $568.5M | $785.0M | ||
| Q3 24 | $561.5M | $786.6M | ||
| Q2 24 | $548.2M | $749.5M | ||
| Q1 24 | $545.7M | $721.8M |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | — | 2.01× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.93× | ||
| Q1 24 | — | 2.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $16.3M |
| Free Cash FlowOCF − Capex | $-18.7M | $16.0M |
| FCF MarginFCF / Revenue | -9.6% | 8.6% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $16.3M | ||
| Q3 25 | $1.0M | $35.7M | ||
| Q2 25 | $-32.4M | $-26.5M | ||
| Q1 25 | $-43.4M | $7.8M | ||
| Q4 24 | $-26.2M | $-3.9M | ||
| Q3 24 | $-18.6M | $-23.0M | ||
| Q2 24 | $-30.1M | $22.7M | ||
| Q1 24 | $-53.5M | $-29.7M |
| Q4 25 | $-18.7M | $16.0M | ||
| Q3 25 | $988.0K | $35.3M | ||
| Q2 25 | $-32.4M | $-28.9M | ||
| Q1 25 | $-43.7M | $7.5M | ||
| Q4 24 | $-26.2M | $-4.2M | ||
| Q3 24 | $-18.7M | $-23.3M | ||
| Q2 24 | $-30.2M | $21.6M | ||
| Q1 24 | $-53.6M | $-31.5M |
| Q4 25 | -9.6% | 8.6% | ||
| Q3 25 | 0.6% | 20.9% | ||
| Q2 25 | -21.6% | -18.7% | ||
| Q1 25 | -36.0% | 6.0% | ||
| Q4 24 | -22.1% | -2.8% | ||
| Q3 24 | -17.9% | -16.5% | ||
| Q2 24 | -34.6% | 17.0% | ||
| Q1 24 | -71.4% | -28.5% |
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.0% | 1.6% | ||
| Q1 25 | 0.3% | 0.2% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.1% | 0.3% | ||
| Q2 24 | 0.1% | 0.9% | ||
| Q1 24 | 0.1% | 1.6% |
| Q4 25 | — | 9.62× | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
